Clinical trials investigating oligometastatic disease
| Identifier | Title | Description | Allocation | Status |
| NCT03965468 | Immunotherapy, chemotherapy, radiotherapy and surgery for synchronous oligo-metastatic NSCLC | Immunotherapy, chemotherapy plus stereotactic radiotherapy to synchronous oligo-metastases followed by definitive surgery or radiotherapy to primary NSCLC | Recruiting | |
| NCT03827577 | OMEGA, local ablative therapy in oligometastatic NSCLC | Resection of primary NSCLC plus local ablative therapy to all metastases versus standard-of-care chemotherapy | Randomised | Recruiting |
| NCT03275597 | Phase Ib study of stereotactic body radiotherapy (SBRT) in oligometastatic non-small lung cancer (NSCLC) with dual immune checkpoint inhibition | SBRT followed by combined durvalumab and tremelimumab | Recruiting | |
| NCT03119519 | Local non-salvage radiotherapy for synchronous oligometastatic non-small-cell lung cancer | Chemotherapy plus local definitive radiotherapy to primary and oligo-metastases versus standard-of-care chemo-/targeted-therapy | Randomised | Recruiting |
| NCT02975609 | Phase II trial of SBRT compared with conventional radiotherapy for oligometastatic non-small cell lung cancer | Chemotherapy plus SBRT versus chemotherapy plus conventional fractionated radiotherapy to primary and all metastatic sites | Randomised | Not yet recruiting |
| NCT02417662 | Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer | Patients will be randomised to receive either standard chemotherapy treatment alone or standard treatment with conventional radiotherapy and SABR | Randomised | Recruiting |
| NCT02054819 | Treating NSCLC minimal stage IV with curative intent | Platinum-based chemotherapy with concurrent radiation therapy to the primary tumour and identified mediastinal lymph nodal metastatic drainage. Local curative radiation will then target the oligometastatic tumour sites | Terminated (low accrual) | |
| NCT01185639 | Stereotactic body radiation therapy (SBRT) in metastatic non-small cell lung cancer | Chemotherapy followed by local ablative radiotherapy to all metastatic lesions | Completed |
NSCLC: nonsmall cell lung cancer; SBRT: stereotactic body radiotherapy; SABR: stereotactic ablative radiotherapy.